All News

Patients with recurrent or progressive high-grade meningioma had encouraging responses to Verzenio in a phase 2 trial.

A 27-year brain tumor survivor shares how mindset, resilience and purposeful action helped her thrive beyond what cancer statistics predicted.

Researchers sought to address a critical gap in the health care system where 85% of U.S. children diagnosed with cancer survive at least five years.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.

Stage 2 essential thrombocythemia is a slow-growing blood cancer managed with monitoring or treatment to reduce clot risk and control symptoms.

Newly diagnosed with cancer? This oncofertility guide covers egg freezing, sperm banking, and critical questions for your oncologist.

Receiving a diagnosis of squamous cell carcinoma can be an overwhelming experience, but it is important to remember that you are not alone.

Small cell lung cancer grows quickly. Learn how it’s diagnosed, staged and treated, and what patients can expect from therapies and side effects.

Patients should understand their cancer, treatment goals and options and record questions to support informed, productive discussions with care teams.

After five years in remission, a scan shows a small anomaly that might be recurrence, or it can show nothing, leaving a tense week before my oncologist visit.

FDA granted breakthrough therapy designation to sofetabart mipitecan for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and chemotherapy.

MammaPrint and BluePrint tests may help identify HR+/HER2– early-stage breast cancer patients likely to benefit from anthracycline-based chemotherapy.

Long-term CATNON trial results show radiotherapy followed by adjuvant temozolomide extends survival in patients with newly diagnosed anaplastic glioma.

Stick your toes in the ocean. Feed the koi. Play make-believe carwash with a toddler. Hold his hand because he asks you to. Be present.

Dr. Anne Peled co-developed the sensation-preserving mastectomy she received after her second diagnosis of breast cancer.

Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making.

Outpatient CD19 CAR-NK plus rituximab led to complete remissions up to 15 months in patients with Waldenström Non-Hodgkin lymphoma.

The allogeneic CAR-T therapy aims to expand urgently needed options for children and adults with aggressive T-cell blood cancers.

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare blood cancer.

CURE spoke with advocate Karen Hoyt about liver cancer, liver disease, and liver health, highlighting silent risk, misconceptions and need for awareness.

Dr. Benjamin Jon Golas outlines pancreatic cancer care, including surgery, chemotherapy, radiation and emerging targeted therapies at specialized centers.

Patient education and individualized navigation can improve genomic testing uptake and downstream participation in genomics-based clinical trials.

A patient with bladder cancer and CLL reflects on how the Japanese art of Ikebana taught acceptance, presence and self-compassion while living with cancer.

A vaccine combined with Keytruda is associated with a 49% reduction in the risk of recurrence or death.

The FDA accepted a new drug application for gedatolisib for patients with HR+, HER2-, PIK3CA wild-type advanced breast cancer.

In patients with high-risk melanoma, intismeran autogene and Keytruda reduced the risk of recurrence or death compared to Keytruda alone.

An expert explains how a DLL3 blood test may help guide Imdelltra use and set expectations for patients with small cell lung cancer.